Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)

ClinicalTrials.gov ID: NCT05144009

Public ClinicalTrials.gov record NCT05144009. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 10:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9)

Study identification

NCT ID
NCT05144009
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
ADC Therapeutics S.A.
Industry
Enrollment
41 participants

Conditions and interventions

Interventions

  • Loncastuximab Tesirine Drug
  • Rituximab Drug

Drug

Eligibility (public fields only)

Age range
65 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 20, 2022
Primary completion
Jan 21, 2024
Completion
Jan 21, 2024
Last update posted
Jan 29, 2025

2022 – 2024

United States locations

U.S. sites
29
U.S. states
16
U.S. cities
27
Facility City State ZIP Site status
University of Arizona Cancer Center Tucson Arizona 85724
Winthrop P. Rockefeller Cancer Institute Little Rock Arkansas 72205
Rocky Mountain Cancer Centers - Aurora Aurora Colorado 80012
USOR - Illinois Cancer Specialists - Niles Niles Illinois 60714
Leonard Lawson Cancer Center Pikeville Kentucky 41501
Cancer Care Specialists - Nevada Reno Nevada 89511
New York Cancer & Blood Specialists - New Hyde Park Babylon New York 11702
New York Cancer & Blood Specialists - Babylon Medical Oncology Port Jefferson New York 11776
Novant Health Cancer Specialists - Charlotte Charlotte North Carolina 28204
USOR - Oncology Hematology Care - Kenwood Cincinnati Ohio 45236
University Hospitals Cleveland Medical Center Cleveland Ohio 44106
Ohio Health - Research and Innovation Institute Columbus Ohio 43210
Willamette Valley Cancer Institute and Research Center - Eugene Eugene Oregon 97401
Reading Hospital - Tower Health Reading Pennsylvania 19611
Prisma Health Cancer Institute Greenville South Carolina 29605
Avera Cancer Institute Sioux Falls South Dakota 57105
Texas Oncology - Austin Midtown Austin Texas 78705
Texas Oncology - Medical City Dallas Dallas Texas 75230
USOR - Texas Oncology - Presbyterian Cancer Center Dallas Dallas Texas 75231
USOR - Texas Oncology - Baylor Charles A. Sammons Cancer Center Dallas Texas 75246
University of Texas MD Anderson Cancer Center Houston Texas 77030
USOR - Texas Oncology - San Antonio San Antonio Texas 78240
Texas Oncology Northeast Texas - Tyler Tyler Texas 75702
Blue Ridge Cancer Care - Blacksburg Blacksburg Virginia 24060
USOR - Virginia Cancer Specialists - Gainesville Office Gainesville Virginia 20155
Virginia Cancer Institute - West End Richmond Virginia 23229
USOR - Virginia Oncology Associates Virginia Beach Virginia 23456
Kadlec Clinic - Hematology and Oncology Richland Washington 99352
USOR - Northwest Cancer Specialists, P.C. dba Compass Oncology - Vancouver Cancer Center Vancouver Washington 98684

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05144009, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 29, 2025 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05144009 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →